Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer - PubMed (original) (raw)
Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer
W H West et al. N Engl J Med. 1987.
Abstract
Adoptive immunotherapy involving bolus-dose recombinant interleukin-2 (rIL-2) has been reported to induce tumor regression in some patients with cancer, but has been associated with severe fluid retention and cardiopulmonary stress. In an effort to preserve the efficacy but reduce the toxicity of this treatment, we used escalating doses of rIL-2 as a constant infusion rather than as a bolus dose. Forty-eight patients with advanced cancer received rIL-2 as a 24-hour infusion in five-day cycles separated by five-day periods of rest and leukapheresis. Eight patients were removed from the study before receiving cells activated in vitro. In the 40 who could be evaluated for their response, there were 13 partial responses (32.5 percent) and 2 minor responses. Partial responses were observed in Hodgkin's disease (one of one), non-Hodgkin's lymphoma (one of one), lung cancer (one of five), ovarian cancer (one of one), parotid cancer (one of two), renal cancer (three of six), and melanoma (five of ten). Responses were associated with a good performance status, a base-line lymphocyte count above 1400 per cubic millimeter, and an rIL-2-induced lymphocyte count of at least 6000. Optimal lymphocytosis required a priming dose of rIL-2 of 3 X 10(6) U per square meter of body-surface area per day, and 15 of 28 patients receiving this priming dose responded to treatment. A weight gain of more than 10 percent of total body weight (five patients) and dyspnea at rest (six patients) were unusual events restricted to patients with poorer pretreatment performance. We conclude that the administration of rIL-2 as a constant infusion may preserve the antineoplastic activity of adoptive immunotherapy while increasing the safety and comfort of patients.
Similar articles
- Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
Stewart JA, Belinson JL, Moore AL, Dorighi JA, Grant BW, Haugh LD, Roberts JD, Albertini RJ, Branda RF. Stewart JA, et al. Cancer Res. 1990 Oct 1;50(19):6302-10. Cancer Res. 1990. PMID: 2205379 Clinical Trial. - A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.
Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, et al. Rosenberg SA, et al. N Engl J Med. 1987 Apr 9;316(15):889-97. doi: 10.1056/NEJM198704093161501. N Engl J Med. 1987. PMID: 3493432 - Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.
Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, et al. Rosenberg SA, et al. N Engl J Med. 1985 Dec 5;313(23):1485-92. doi: 10.1056/NEJM198512053132327. N Engl J Med. 1985. PMID: 3903508 Clinical Trial. - Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes.
Rosenberg SA, Lotze MT. Rosenberg SA, et al. Annu Rev Immunol. 1986;4:681-709. doi: 10.1146/annurev.iy.04.040186.003341. Annu Rev Immunol. 1986. PMID: 3518753 Review. No abstract available. - The adoptive immunotherapy of cancer using the transfer of activated lymphoid cells and interleukin-2.
Rosenberg SA. Rosenberg SA. Semin Oncol. 1986 Jun;13(2):200-6. Semin Oncol. 1986. PMID: 3520827 Review. No abstract available.
Cited by
- Induction of lymphokine-activated killer cytotoxicity with interleukin-2 and tumor necrosis factor-alpha against primary lung cancer targets.
Yang SC, Owen-Schaub L, Grimm EA, Roth JA. Yang SC, et al. Cancer Immunol Immunother. 1989;29(3):193-8. doi: 10.1007/BF00199995. Cancer Immunol Immunother. 1989. PMID: 2543502 Free PMC article. - The development of new immunotherapies for the treatment of cancer using interleukin-2. A review.
Rosenberg SA. Rosenberg SA. Ann Surg. 1988 Aug;208(2):121-35. doi: 10.1097/00000658-198808000-00001. Ann Surg. 1988. PMID: 3041925 Free PMC article. Review. - Inhibition of lymphokine-activated killer cell generation by blocking factors in sera of patients with head and neck cancer.
Bugis SP, Lotzová E, Savage HE, Hester JP, Racz T, Sacks PG, Schantz SP. Bugis SP, et al. Cancer Immunol Immunother. 1990;31(3):176-81. doi: 10.1007/BF01744733. Cancer Immunol Immunother. 1990. PMID: 2337906 Free PMC article. - Effects of interleukin 2 on cardiac function in the isolated rat heart.
Sobotka PA, McMannis J, Fisher RI, Stein DG, Thomas JX Jr. Sobotka PA, et al. J Clin Invest. 1990 Sep;86(3):845-50. doi: 10.1172/JCI114783. J Clin Invest. 1990. PMID: 2394834 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources